肿瘤微环境中的脂肪酸重编程中性粒细胞,在小鼠中诱导腺苷介导的免疫抑制
Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice
研究在小鼠晚期结直肠癌模型中发现一条肿瘤来源脂质—中性粒细胞—腺苷轴:肿瘤间质液中富集的脂肪酸通过 PPARα 激活使中性粒细胞上调 CD39 和 CD73 并生成腺苷,最终抑制 T 细胞。A2aR/A2bR 双重腺苷受体拮抗剂 AB928 在体外和体内恢复 T 细胞增殖、效应功能与肿瘤杀伤能力。AB928 与 anti-PD-1 联用还在免疫治疗耐药的转移性结直肠癌自发模型中延长了动物生存。
研究在小鼠结直肠癌模型中串联肿瘤脂肪酸、中性粒细胞 PPARα 与腺苷生成,为免疫治疗耐药提供代谢层面的解释。
已发表论文 · journal · 10.1038/s41467-026-78771-8
本站摘要基于收录版本 v1(2026-10-26),原始摘要与 AI 导读固定保留。
IF(5) 18.9 · 2025 · 期刊参考指标
摘要翻译暂不可用,暂时显示原文。
Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice
As solid tumors progress, the tumor microenvironment becomes increasingly immunosuppressive, impairing cytotoxic T-cell activity and limiting the efficacy of immune checkpoint blockade. However, the mechanistic drivers of this immunosuppression remain poorly understood. Here, we identify a tumor-derived lipid–neutrophil–adenosine axis as a critical regulator of immune suppression in advanced colorectal cancer (CRC). We show that fatty acids enriched in tumor interstitial fluid reprogram neutrophils toward an immunosuppressive phenotype through PPARα activation, upregulation of CD39 and CD73, and adenosine generation, ultimately leading to T-cell suppression. AB928, a dual A2aR/A2bR adenosine receptor antagonist currently in clinical trials, restores T-cell proliferation, effector function, and tumor-killing capacity in vitro and in vivo. Importantly, AB928 synergizes with anti-PD-1 therapy to enhance survival in an immunotherapy-resistant autochthonous model of metastatic CRC. Thus, our findings define a metabolic immune evasion mechanism in the microenvironment and provide a rationale for targeting neutrophil-derived adenosine signaling to improve immunotherapy responses in CRC. Lipid accumulation in solid tumors supports tumor progression by promoting immune evasion. Yet the molecular basis of this lipid-mediated immunosuppression remains unclear. Here, using murine models of advanced colorectal cancer, the authors uncover a metabolic-immune axis whereby tumor-derived fatty acids activate neutrophil PPARα, resulting in adenosine generation and T cell suppression. Importantly, treatment with a dual adenosine receptor antagonist restores T cell-mediated antitumor immunity and synergizes with anti-PD-1 therapy to enhance animal survival.
来源:Nature Communications · doi.org